|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.44 CNY | +0.39% |
|
-7.29% | +23.45% |
| 05-19 | Gan & Lee Pharmaceuticals Completes First Patient Dosing in GZR102 Trial | MT |
| 04-25 | Gan & Lee Pharmaceuticals' 2024 Profit Jumps 81%, Operating Income Rises 17%; Shares Jump 10% | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility (Composite) | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
| 2 | ||||||||
| 17 | ||||||||
| 25 | ||||||||
| 17 | ||||||||
| 31 | ||||||||
| 28 | ||||||||
| 2 | ||||||||
| - | - | |||||||
| 23 | ||||||||
| - | 1 | |||||||
| 28 | ||||||||
| 11 | ||||||||
| 19 | ||||||||
| 13 | ||||||||
| 9 | ||||||||
| 6 | ||||||||
| 1 | ||||||||
| 2 | ||||||||
| 3 | ||||||||
| Average | 13 | |||||||
| Weighted average by Cap. | 17 |
- Stock Market
- Equities
- 603087 Stock
- Sector Gan & Lee Pharmaceuticals.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition